오스코텍

039200KOSDAQ

60.5 / 100

Reference Date: 2026-09-08

Financial Score23.5 / 40

News Sentiment19.0 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly up 2.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Oskotech is a research-focused biopharmaceutical company specializing in new drug development, functional materials, and dental bone grafts. It is currently conducting clinical trials for two synthetic drug candidates and holds a targeted anti-cancer drug approved by the US FDA. Major revenue streams come from technology transfer milestones and royalty income.

Number of Employees

57people

Average Salary

61.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

26.28Industry Average 15.001.5Point

1.8x industry avg (risky)

PBR

7.36Industry Average 1.200.0Point

6.1x industry avg (risky)

ROE

34.08Industry Average 8.007.0Point

4.3x industry avg (excellent)

Debt Ratio

2.16Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲390.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲1048.3% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.1% (improving, 3yr)

Detailed News Sentiment

15 totalPositive 11Neutral 4Negative 0Average Sentiment Score 76

Positive
오스코텍, 알츠하이머 신약 임상 사노피와 '바통터치'
오스코텍의 알츠하이머 신약 임상 결과 조기 성공으로 기술이전이 이루어져 긍정적인 시장 반응을 이끌어냈다.
Positive
K바이오 기술 수출 벌써 21兆…역대 최대 실적 기대
오스코텍의 기술 수출 규모가 증가함에 따라 관련 제약바이오 산업 전반의 긍정적 전망이 기대됩니다.
Positive
신약 하나보다 '플랫폼'으로 승부…제약바이오 전략 바뀐다
오스코텍의 동아쏘시오그룹과의 협력으로 AI 기반 신약 플랫폼 구축이 발표되어 미래 성장 가능성이 높아졌다.

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 35,950Won52-week high 62,00052-week low 28,000

1-month return4.0Point

1m +2.86% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral투자판단관련주요경영사항(임상시험결과) (알츠하이머 치료 후보물질 ADELY01 임상 1a/1b상 임상시험결과보고서(CSR) 수령)2026-09-04
Neutral주식등의대량보유상황보고서(일반)2026-09-01
Neutral기업설명회(IR)개최2026-08-20
Neutral주식등의대량보유상황보고서(일반)2026-08-14
Neutral반기보고서 (2026.06)2026-08-14